Search for: "In re Books-A-Million, Inc. Stockholders Litigation" Results 1 - 20 of 27
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
21 Aug 2023, 4:34 am by Peter Mahler
The point is, given the discrete, fixed-in-time nature of the oppressive acts, rare is the minority shareholder who doesn’t know they’re being oppressed when they’re being oppressed. [read post]
16 Feb 2021, 2:23 pm by Kevin LaCroix
San Francisco Nov. 16, 2020), and In re Dropbox, Inc. [read post]
16 Mar 2020, 1:54 pm by Kevin LaCroix
An early example of Lorenzo having an impact (albeit short-lived) in private litigation is In re Longfin Corp Sec. [read post]
3 Sep 2019, 3:39 am by Franklin C. McRoberts
Before his death in 2010, Brown transferred millions of dollars to a trust. [read post]
19 Jul 2019, 1:00 am by Doug Cornelius
The Delaware Supreme Court, applying the ‘duty to monitor’ doctrine enunciated in In re Caremark International, Inc. [read post]
31 May 2019, 8:39 am by Carl Neff
On May 31, 2019, the Court of Chancery issued a 57-page memorandum opinion ordering Facebook Inc. to provide certain corporate books and records to various plaintiff investors, in the case of In re Facebook Inc. [read post]
24 Jan 2019, 2:36 pm by Kevin LaCroix
”   Enforcement Litigation and Administrative Proceedings Just about all SEC litigation and administrative proceedings must now pause indefinitely. [read post]
2 Jul 2018, 3:18 am by Peter Mahler
Pennsylvania: The Hornberger Case Hornberger v Dave Gutelius Excavating, Inc., 2017 PA Super 395 [Super. [read post]
8 Dec 2016, 12:07 pm by Francis Pileggi
The post Claims Barred Pursuant to Settlement Agreement and Res Judicata. appeared first on Delaware Corporate & Commercial Litigation Blog. [read post]
9 Aug 2016, 10:44 am by Chris Castle
 After that elevation, her portfolio still includes Litigation Section III–run by a lawyer named David C. [read post]
27 Jun 2012, 11:33 am by Francis Pileggi
Finally, a review of the details of the decision follows: Background of Pyott case: In September 2010, Allergan, Inc. entered into a settlement with the United States Department of Justice and pled guilty to criminal misdemeanor misbranding and paid a total of $600 million in civil and criminal fees. [read post]